Hexarelin is a synthetic hexapeptide growth hormone secretagogue and one of the most potent GH-releasing peptides developed. It acts on the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the pituitary gland. Hexarelin is distinguished by its notably strong cardioprotective properties, independent of its GH-releasing effects. Research has shown Hexarelin protects cardiac tissue through activation of specific cardiac receptors and modulation of calcium handling. Unlike some other GHRPs, Hexarelin maintains its GH-releasing efficacy with repeated administration, though it may still be subject to some desensitization over extended use periods.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 20-30 minutes |
| Administration | Subcutaneous injection |
| Typical Dosage | 100-200 mcg |
| Molecular Weight | 887.0 Da |
| Molecular Formula | C47H58N12O6 |
Highly potent ghrelin receptor agonist with strongest GH release among GHRPs. Causes rapid receptor desensitization.
All information is presented for Research Use Only (RUO). Not medical advice.